{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:24Z","timestamp":1790790264719,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Aging","award":["1R13AG082492-01"],"award-info":[{"award-number":["1R13AG082492-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02891-0","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:03:06Z","timestamp":1717488186000},"page":"2723-2742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-6536","authenticated-orcid":false,"given":"Prem","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9616","authenticated-orcid":false,"given":"Adrian","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-8962","authenticated-orcid":false,"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-920X","authenticated-orcid":false,"given":"L. J.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-3003","authenticated-orcid":false,"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-2691","authenticated-orcid":false,"given":"Michelle","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-2979","authenticated-orcid":false,"given":"Dhruv","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-3652","authenticated-orcid":false,"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-0359","authenticated-orcid":false,"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5716-9443","authenticated-orcid":false,"given":"Rosalyn","family":"Adigun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8564-6187","authenticated-orcid":false,"given":"Preston","family":"Dunnmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8943-3395","authenticated-orcid":false,"given":"Jeffery","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Amyloidosis Forum Meeting Panelists","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"McCausland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette","family":"Henshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Azzarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Polydefkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee P.","family":"Bullock-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Gandotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Zouridakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Race","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sakushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jawidzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motiur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman L.","family":"Stockbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiley","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Slugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Meldorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"1","key":"2891_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","volume":"71","author":"J Rubin","year":"2020","unstructured":"Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020;71(1):203\u201319.","journal-title":"Annu Rev Med"},{"issue":"22","key":"2891_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2891_CR3","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circulation. 2019;12(9):e006075.","journal-title":"Circulation"},{"issue":"24","key":"2891_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"4","key":"2891_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512\u201326.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2891_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2891_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"issue":"22","key":"2891_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20\u00a0years. Circulation. 2022;146(22):1657\u201370.","journal-title":"Circulation"},{"issue":"23","key":"2891_CR9","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361\u201371.","journal-title":"N Engl J Med"},{"issue":"36","key":"2891_CR10","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2891_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1163","volume":"18","author":"T Martyn","year":"2022","unstructured":"Martyn T, Rubio AC, Estep JD, Hanna M. Opportunities for earlier diagnosis and treatment of cardiac amyloidosis. Methodist Debakey Cardiovasc J. 2022;18(5):27\u201339.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"2891_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2891_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"2891_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"issue":"11","key":"2891_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"2891_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"2891_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14797\/mdcvj.1050","volume":"18","author":"LK Stern","year":"2022","unstructured":"Stern LK, Patel J. Cardiac amyloidosis treatment. Methodist Debakey Cardiovasc J. 2022;18(2):59\u201372.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"2891_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13023-020-01525-2","volume":"15","author":"I Lousada","year":"2020","unstructured":"Inaugural Amyloidosis Forum Panelists, Lousada I. The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet J Rare Dis. 2020;15(1):268.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2891_CR19","volume":"15","author":"MS Maurer","year":"2022","unstructured":"Maurer MS, Dunnmon P, Fontana M, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group. Circulation. 2022;15(6):e009038.","journal-title":"Circulation"},{"key":"2891_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/PROM.S399658","volume":"14","author":"AAWM Rizio","year":"2023","unstructured":"Rizio AAWM, D\u2019Souza A, Hsu K, et al. Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023;14:153\u201369.","journal-title":"Patient Relat Outcome Meas"},{"key":"2891_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02637-4","author":"ML Mauermann","year":"2023","unstructured":"Mauermann ML, Clarke JO, Litchy WJ, et al. Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the Amyloidosis Forum Multi-organ System Working Group. Adv Ther. 2023. https:\/\/doi.org\/10.1007\/s12325-023-02637-4.","journal-title":"Adv Ther"},{"issue":"30","key":"2891_CR22","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"issue":"3","key":"2891_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng RK, Levy WC, Vasbinder A, et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol. 2020;2(3):414\u201324.","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2891_CR24","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","volume":"8","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Judge DP, Hoffman JE, et al. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021;8(5):3875\u201384.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"2891_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","volume":"8","author":"BW Sperry","year":"2023","unstructured":"Sperry BW, Hanna M, Maurer MS, et al. Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2023;8(3):275\u201380.","journal-title":"JAMA Cardiol"},{"issue":"27","key":"2891_CR26","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","volume":"43","author":"S Law","year":"2022","unstructured":"Law S, Bezard M, Petrie A, et al. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022;43(27):2622\u201332.","journal-title":"Eur Heart J"},{"issue":"8","key":"2891_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","volume":"87","author":"Y Sekijima","year":"2016","unstructured":"Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87(8):773\u201381.","journal-title":"Neurology"},{"issue":"7","key":"2891_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/genes12070955","volume":"12","author":"AM Minnella","year":"2021","unstructured":"Minnella AM, Rissotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes (Basel). 2021;12(7):955.","journal-title":"Genes (Basel)"},{"issue":"2","key":"2891_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"LF Maia","year":"2015","unstructured":"Maia LF, Magalh\u00e3es R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86(2):159\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2891_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00415-017-8668-8","volume":"265","author":"A Martins da Silva","year":"2018","unstructured":"Martins da Silva A, Cavaco S, Fernandes J, et al. Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. J Neurol. 2018;265(2):299\u2013307.","journal-title":"J Neurol"},{"issue":"2","key":"2891_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","volume":"25","author":"C Monteiro","year":"2018","unstructured":"Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (pTTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120\u20138.","journal-title":"Amyloid"},{"issue":"10","key":"2891_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2891_CR33","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"issue":"20","key":"2891_CR34","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"12","key":"2891_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"2891_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.751","author":"S Chatur","year":"2023","unstructured":"Chatur S, Vaduganathan M, Claggett BL, et al. Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation. 2023. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.751.","journal-title":"Circulation"},{"issue":"11","key":"2891_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13598","volume":"51","author":"A Aimo","year":"2021","unstructured":"Aimo A, Rapezzi C, Perfetto F, et al. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. Eur J Clin Invest. 2021;51(11):e13598.","journal-title":"Eur J Clin Invest"},{"issue":"5 Pt 1","key":"2891_CR38","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","volume":"158","author":"PL Enright","year":"1998","unstructured":"Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2891_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1167\/iovs.07-1132","volume":"49","author":"KG Csaky","year":"2008","unstructured":"Csaky KG, Richman EA, Ferris FL III. Report from the NEI\/FDA ophthalmic clinical trial design and endpoints symposium. Invest Ophthalmol Vis Sci. 2008;49(2):479\u201389.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"23","key":"2891_CR40","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","volume":"388","author":"M Fontana","year":"2023","unstructured":"Fontana M, Gilbertson J, Verona G, et al. Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy. N Engl J Med. 2023;388(23):2199\u2013201.","journal-title":"N Engl J Med"},{"issue":"4","key":"2891_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD. Cox\u2019s regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100\u201320.","journal-title":"Ann Stat"},{"issue":"4","key":"2891_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","volume":"62","author":"DY Lin","year":"2000","unstructured":"Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J Roy Stat Soc Ser B (Statistical Methodology). 2000;62(4):711\u201330.","journal-title":"J Roy Stat Soc Ser B (Statistical Methodology)"},{"issue":"408","key":"2891_CR43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","volume":"84","author":"LJ Wei","year":"1989","unstructured":"Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84(408):1065\u201373.","journal-title":"J Am Stat Assoc"},{"issue":"Suppl L","key":"2891_CR44","doi-asserted-by":"publisher","first-page":"L77","DOI":"10.1093\/eurheartj\/suaa140","volume":"22","author":"E Gronda","year":"2020","unstructured":"Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020;22(Suppl L):L77\u2013L81.","journal-title":"Eur Heart J Suppl"},{"issue":"10","key":"2891_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200047","volume":"1","author":"BL Claggett","year":"2022","unstructured":"Claggett BL, McCaw ZR, Tian L, et al. Quantifying treatment effects in trials with multiple event-time outcomes. NEJM Evid. 2022;1(10):EVIDoa2200047.","journal-title":"NEJM Evid"},{"key":"2891_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ahj.2021.03.016","volume":"241","author":"Y Chen","year":"2021","unstructured":"Chen Y, Lawrence J, Stockbridge N. Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials. Am Heart J. 2021;241:108\u201319.","journal-title":"Am Heart J"},{"key":"2891_CR47","doi-asserted-by":"publisher","unstructured":"Signorovitch J, et al. Pathway for development and validation of multi-domain endpoints for amyloid light chain (AL) amyloidosis. Ther Innov Regul Sci. https:\/\/doi.org\/10.1007\/s43441-024-00641-6.","DOI":"10.1007\/s43441-024-00641-6"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02891-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:42:26Z","timestamp":1719571346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02891-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2891"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02891-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mathew Maurer: Grant support from NIH R01HL139671 and R01AG081582-01; grants and personal fees from Alnylam, Pfizer, Eidos, Prothena, and Ionis; and personal fees from AstraZeneca, Akcea, Intellia, and Novo-Nordisk. Prem Soman: Grant support Pfizer; Personal fees from Alnylam and BridgeBio. Adrian Hernandez: Consultant\/scientific advisor to Amgen, AstraZeneca, Bayer, Bioforumis, Bristol Myer Squibb, Boehringer Engelheim, Boston Scientific, Cytokinetics, Eidos\/Bridgebio, GlaxoSmith Kline, Intercept Pharmaceuticals, Intellia Therapeutics, MyoKardia, Novartis, NovoNordisk, Pfizer and TikkunLev. Research support from American Heart Association, Aires Pharmaceuticals, Amgen, American Regent, AstraZeneca, Boehringer Engelheim, Bristol-Myers Squibb, Cytokinetics, Intellia Therapeutics, Genentech, GlaxoSmithKleine, Merck, National Heart, Lung, and Blood Institute (NHLBI), Novartis, Patient-Centered Outcomes Research Institute (PCORI), Pfizer and Verily. Pablo Garcia-Pavia: Speaking fees from Pfizer, BridgeBio, Ionis Pharmaceuticals, AstraZeneca, NovoNordisk, Intellia and Alnylam Pharmaceuticals, consulting fees from Pfizer, BridgeBio, Neuroimmune, Alnylam Pharmaceuticals, AstraZeneca, NovoNordisk, ATTRalus, Intellia, General Electric and Alexion, and research\/educational support to his institution from Pfizer, BridgeBio and Alnylam Pharmaceuticals. James Signorovitch: Employee of Analysis Group Inc., which provides research and consulting services to biopharma and has received consulting fees from ARC. Mazen Hanna: Served on advisory boards for Pfizer, BridgeBio, Ionis Pharmaceuticals, and Alexion Pharmaceuticals. Frederick Ruberg: Research support: NIH\/NHLBI (R01 HL139671), Pfizer, Akcea\/Ionis, Alnylam Consulting: ATTRalus, AstraZeneca. Sharmila Dorbala: Grant support from NIH; grants from Pfizer, ATTRalus, Siemens, Phillips; Consulting fees from Pfizer, Novo-Nordisk, BridgeBio. Jeffery Kelly: Consultant\/scientific advisor to ATTRalus, George E. Hewitt Foundation for Medical Research, NeoChromosome, Pfizer, Protego, Curebound, Yumanity. Board of Directors member for George E. Hewitt Foundation for Medical Research, Protego, Yumanity. Stock in NeoChromosome, Pfizer, Protego, Yumanity. Julian Gillmore: Consultancy fees from Alnylam, Pfizer, BridgeBio, Ionis, AstraZeneca, ATTRalus, Intellia, Lycia. L J Wei, Michelle Kittleson, Dhruv Kazi, Kristen Hsu, Isabelle Lousada, Rosalyn Adigun, Preston Dunnmon have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The information contained in this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Permission was received by the Amyloidosis Forum to publish this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}